Cost Effectiveness of Inhaled Corticosteroid plus Bronchodilator Therapy versus Bronchodilator Monotherapy in Children with Asthma
- 7 Downloads
In an incremental cost-effectiveness analysis. combined inhaled β2-receptor agonist plus inhaled coricosteroid therapy (BA + CS) was compared with inhaled β2-agonist plus placebo (BA + PL) in 116 asthmatic children aged 7 to 16 years. Clinical data have been reported previously. To account for the selective withdrawal rate due to pulmonary problems that occurred in the group receiving BA + PL costs were calculated using 2 approaches: (1) the cumulative cost approach and (2) the patient-year approach.
Besides improvements in forced expiratory volume in 1 second (FEV1) and airway responsiveness expressed as the provocative dose of histamine required to give a 20% fall in FEV1 (PD20). the frequency of asthma symptoms and school absenteeism were significantly reduced in the BA + CS group. Annual drug acquisition costs for the group receiving BA + CS were NLG480 higher than for the BA + PL group ($US1 = NLG2.12, 1989 prices). Based on conservative calculations using the cumulative cost approach, annual savings due to reduced healthcare utilisation. excluding the cost of study drugs, by the group receiving BA + CS compared with BA + PL were estimated to be about NLG273 per patient. The incremental cost effectiveness of BA + CS was estimated to be about NLG17S per 10% increase in FEV1, or somewhat less than NLG10 per symptom-free day gained. The patient-year approach estimated savings due to conicosteroids of about 43% of the costs of BA + PL (95% confidence intervals, 21 to 58%). Savings were larger when the indirect costs that a family incurred during school absenteeism were considered.
Addition of an inhaled corticosteroid 10 an inhaled β2-receptor agonist is a cost-effective treatment option that could even result in net healthcare savings.
KeywordsAsthma Budesonide Asthmatic Child Cromoglycate Sodium Cromoglycate
Unable to display preview. Download preview PDF.
- Armitage P, Berry G. Statistical methods in medical research. Blaekwell Scientific Publications, Oxford, 1987Google Scholar
- Buxton MJ. Problems in the economic appraisal of new technology: the evaluation of heart transplants in the UK. In Dnimmond (Ed.) Economic appraisal of health technology in the European Community, p. 115. Oxford University Press, Oxford, 1987Google Scholar
- Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate and betamethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to histamine. Journal of Allergy and Clinical Immunology 79: 734–740, 1987PubMedCrossRefGoogle Scholar
- Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, 1987Google Scholar
- Furukawa CT, Shapiro GG, Bierman CW, Kraemer MJ, Ward DJ, et al. A double blind study comparing the effectiveness of cromolyn sodium and sustained release theophylline in childhood asthma. Paediatrics 74: 453–459, 1984Google Scholar
- Jackson RT, Mitchell EA. Trends in hospital admission rates and drug treatment of asthma in New Zealand. New Zealand Medical Journal 96: 727–729, 1983Google Scholar
- Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O’Bryne PM, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. American Review of Respiratory Disease 142: 832–836, 1990PubMedGoogle Scholar
- Lako CJ. Absenteeism in primary school. Tijdschrifl voor Sociale Gezondheidszorg 61: 776–783, 1983Google Scholar
- National Heart Lung and Blood Institute (National Institutes of Health) expert panel. Guidelines for the diagnosis and management of asthma, journal of Allergy and Clinical immunology 88 (Part 2, Suppl,): 425–492, 1991Google Scholar
- Rice DP, Hodgson TA, Kopsten AN. The economic costs of illness: a replication and update. Health Care Financing 7: 61–80, 1985Google Scholar
- Seiroos O. The effects of inhaled corticosteroids on the natural history of obstructive lung diseases. European Respiratory Review 1: 354–365, 1991Google Scholar
- STG. Chronic diseases in the year 2005. Part 2: Scenarios for chronic non-specific lung disease 1990–2005. In Dutch. Bohn Stafleu van Loghum, Houtcn/Antwerpen, 1990Google Scholar
- Svendsen UG, Frolund L, Madsen F, Nielsen NH, Hotslein-Rathlou N-H, Weeke B. A comparison of the effects of sodium cromoglycate and beclomethasone dipropionate on pulmonary function and bronchial hyperreactivity in subjects with asthma. Journal of Allergy Clinical Immunology 80: 68–74, 1987CrossRefGoogle Scholar
- Van Doorslaer EKA, Rutten FFH, Haan G. Economic evaluation of preventive health care. Is one ounce prevention worth one pound of therapy? In Lapre et al. (Eds) The economics of preventive health care. Conference report of the Society for Health Economics, De Tijdstroom, Lochem, Gent, 1988Google Scholar
- Van Essen-Zandvliet EE, Kerrebijn KF. The effect of anti-asthma drugs on bronchial hyperresponsiveness. Immunology and Allergy Clinics of North America 10: 483–501, 1990Google Scholar
- Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, et al. and the Dutch Chronic Non-Specific Lung Disease Study Group. Effects of 22 months treatment with inhaled corticosteroids and/or beta2-agonists on lung function, airway responsiveness and symptoms in children with asthma. American Review of Respiratory Disease 146: 547–5S4, 1992PubMedGoogle Scholar
- Wever-Hess J, Wever AMJ, Yntema JL. Mortality and morbidity from respiratory diseases in childhood asthma in the Netherlands, 1980-1987. European Respiratory Journal 9: 429–433, 1991Google Scholar
- Wokhers OD, Pcdersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticoids. Paediatrics 89: 839–842, 1992Google Scholar